Canadian Left Atrial Appendage Closure Study

NCT ID: NCT03133806

Last Updated: 2017-04-28

Basic Information

• Recruitment Status: UNKNOWN
• Clinical Phase: NA
• Total Enrollment: 30 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2017-02-15
• Study Completion Date: 2018-08-15

Brief Summary

The purpose of the study is to demonstrate the safety and the rate of closure of the Ultrasept Left Atrial Appendage (LAA) Closure System for the percutaneous occlusion of the left atrial appendage in patients with non-valvular atrial fibrillation.

Detailed Description

The CLASS study is a multicenter, prospective, single arm trial designed to demonstrate the feasibility and short term efficacy of the Ultrasept Left Atrial Appendage Closure Device. Patients who present or are referred for participation in the study will be evaluated against the inclusion and exclusion criteria. Those meeting the criteria will be given the opportunity to participate. All patients will have protocol-required evaluations at each scheduled follow-up.

Conditions

Left Atrial Appendage; Non-Valvular Atrial Fibrillation

Keywords

Percutaneous Occlusion

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Ultrasept LAA Closure System

Interventional percutaneous transcatheter device.

Group Type: EXPERIMENTAL

Ultrasept LAA Closure System

Intervention Type: DEVICE

The Ultrasept Left Atrial Appendage Closure System Device is a percutaneous transcatheter device intended to prevent thrombus embolization from the left atrial appendage (LAA) in patients with non-valvular atrial fibrillation.

Interventions

Ultrasept LAA Closure System

The Ultrasept Left Atrial Appendage Closure System Device is a percutaneous transcatheter device intended to prevent thrombus embolization from the left atrial appendage (LAA) in patients with non-valvular atrial fibrillation.

Intervention Type: DEVICE

Other Intervention Names

Ultrasept, Ultrasept LAA Closure Device

Eligibility Criteria

Inclusion Criteria

• Subject has a documented history of paroxysmal, persistent or permanent non-valvular atrial fibrillation.
• Subject is able to provide informed consent for the procedure.
• Subject is able to be followed for the duration of the study.
• Patient is able to take aspirin and Clopidogrel. Expected duration of dual antiplatelet therapy of 45 days.
• Patient is not able to tolerate or adhere to the requirements of long term anticoagulation therapy.
• Subject has a CHADS score >/= 1.

Exclusion Criteria

• The patient is known to have an extensive congenital cardiac anomaly which can only be adequately repaired by way of cardiac surgery.
• The patient's size (i.e., too small for TEE probe, catheter size, etc.) or condition (active infection, etc.) would cause the patient to be a poor candidate for cardiac catheterization.
• LAA anatomical exclusion (depth <16mm and/or diameter <11mm).
• Patients with recent myocardial infarction, unstable angina, or decompensated congestive heart failure. (Recent is defined as within 180 days of implant date).
• Patients with any type of serious infection less than one month prior to procedure.
• Patient has demonstrated intracardiac thrombi on echocardiography (especially left atrial or left atrial appendage thrombi).
• Patient is participating in another investigational drug or device study.
• Subject has an implanted atrial septal defect (ASD) device or patent foramen ovale (PFO) device.
• Subject had surgical ASD or PFO repair.
• Subject has a moderate to severe aortic or mitral valve stenosis or regurgitation as assessed by the investigator.
• Subject has a planned ablation procedure for atrial fibrillation within 60 days after the Ultrasept LAA closure device implant.
• Subject has a New York Heart Association (NYHA) grade 4.
• Patient has a left ventricular ejection fraction of 20% or less.
• Patient has a life expectancy of less than one year.
• Subject has had a recent major cardiac surgical procedure (recent is defined as within 180 days of implant date).
• Subject is pregnant, breastfeeding, or desires to become pregnant during their first 180 days post-implant.
• Subject has a medical disorder that would interfere with completion or evaluation of clinical study results (for e.g. uncontrolled hypertension, uncontrolled diabetes, renal failure, in situ inferior vena cava filter).
• Patient has an allergy to Nickel.

• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Cardia Inc.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Reda Ibrahim, MD

Role: PRINCIPAL_INVESTIGATOR

Montreal Heart Institute

Jean-Bernard Masson, MD FRCPC

Role: PRINCIPAL_INVESTIGATOR

Centre hospitalier de l'Université de Montréal (CHUM)

Josep Rodés-Cabau, MD

Role: PRINCIPAL_INVESTIGATOR

Quebec Heart & Lung Institute Laval University

Locations

Quebec Heart & Lung Institute Laval University

Québec, , Canada

Site Status: RECRUITING

Countries

Canada

Central Contacts

Vice President of Operations

Role: CONTACT

Phone: 651-691-4100

Email: cardia@cardia.com

Facility Contacts

Emilie Pelletier Beaumont, M. Sc.

Role: primary

Other Identifiers

CLIN-2026

Identifier Type: -

Identifier Source: org_study_id